The substance semaglutide has been approved as a diabetes drug in Germany for five years.  Under the trade name "Wegovy", it helps overweight people to lose weight. In recent months, it has been highlighted in the media as a "weight loss injection".

In an online event in the 'SZ Gesundheitsforum' series this evening, December 11, 2023, starting at 7:30 p.m., the science editor of the Süddeutsche Zeitung, Dr. Christina Berndt, together with experts, will shed light on who it is useful for, what side effects can occur and whether it can replace other treatments such as stomach reduction for severe obesity.

DZD scientists Prof. Dr. Matthias Blüher and PD Dr. Timo Müller will also be attending. Blüher is head of the Helmholtz Munich Institute for Metabolism, Obesity and Vascular Research at the University of Leipzig and Leipzig University Hospital and an expert on the metabolism of obesity. Müller heads the Institute of Diabetes and Obesity at Helmholtz Munich. He investigates the role of hormones in obesity and weight loss.

Questions can be sent in in advance or asked during the event.

Participation is free of charge, but you must register for the livestream.

Further information and registration (in German)